October 24, 2018 / 2:23 PM / 24 days ago

Forward Pharma loses appeal in Tecfidera patent dispute with Biogen

Oct 24 (Reuters) - A U.S. appeals court on Wednesday upheld a ruling that patents owned by Biogen Inc covering its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S.

The U.S. Court of Appeals for the Federal Circuit said it agreed with a March 2017 ruling by the Patent Trial and Appeal Board that freed Bigoen Inc from future royalty payments to Forward.

Reporting by Jan Wolfe Editing by Chizu Nomiyama

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below